URL copied
Roche s Covid antibody cocktail launched in India for treatment of mild to moderate cases
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.
Used in treatment of mild to moderate Covid-19 in adults and pediatric patients (12 years and older)Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June.
In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the prodmidluct by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers.
The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody
Roche s COVID-19 antibody cocktail launched in India at Rs 59,750 per dose
Antibody cocktail is to be administered for treatment of mild to moderate coronavirus disease in adults and pediatric patients who are confirmed to be infected with SARS-COV2 and are at high risk of developing severe COVID-19 disease and do not require oxygen
BusinessToday.In | May 24, 2021 | Updated 11:41 IST
Cocktail has been shown to help high-risk Covid patients before their condition worsens
Roche India and Cipla Limited, in a joint statement today, said the first batch of the antibody cocktail Casirivimab and Imdevimab is now available in India, while a second batch will be made available by mid-June. The price for each patient dose, a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab), will be Rs 59,750, inclusive of all taxes. The MRP for the multi dose pack, each pack can treat two patients, is Rs 119,500.
Roche’s antibody cocktail launched in India at ₹59,750/dose
PTI
New Delhi |
Updated on
May 24, 2021
Cipla to market drug in country
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at ₹59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk.
“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement. Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.
UPDATED: May 24, 2021 13:51 IST
The drug will be available through leading hospitals and Covid treatment centers. (Photo: PTI/ for Representation)
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.